secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001808805-25-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%
--------------------------------------------------------------------------------

- Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
- Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.
- Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).
- Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.
- Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/naut-20250224.htm
  HTML page:      https://secwatch.observer/filing/0001808805-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer